research Reporting on Adverse Clinical Events
This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.
Search
for
Sort by
Research
180-210 / 1000+ results research 胃切除・腸切除術後の退院指導-パンフレットを使用して-
This study found that specific residues in human steroid 5alpha-reductase types 1 and 2 influence substrate binding and resistance to the inhibitor Finasteride, with certain substitutions significantly affecting these interactions.
research New 5?-reductase inhibitors: In vitro and in vivo effects
This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.
research The safety of 52 weeks of oral DHEA therapy for postmenopausal women
This study found that taking a daily oral dose of 50mg DHEA for one year had no significant impact on blood lipids, insulin sensitivity, or the endometrium in postmenopausal women with low libido.
research Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
research Antihormonal properties of some new A-homo-B, 19-dinor steroids of the androstane series
The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.
research Multi-target evaluation of Korean herbal compounds against the SRD5A2 / AR / beta-catenin axis for androgenetic alopecia: Boltz-2 cofold, ChEMBL-anchored ranking, ADMET-AI 107-endpoint safety panel, and pilosebaceous single-cell atlas-constrained prioritization of Saponin Re, Emodin, and Biochanin A
This study conducted an in silico evaluation of Korean herbal compounds against key targets involved in androgenetic alopecia, finding Biochanin A, Saponin Re, and Emodin as promising candidates for topical treatments, but highlighting safety and topical formulation challenges.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.